Diversifying Blue-Chip Portfolio
Pictet Asset Management Boosts Stakes in Utility Giants, Makes Major AstraZeneca Investment
Key Points
Ameren: Pictet Asset Management Holding SA increased its Ameren stake to 2,268,081 shares after adding 270,937 during Q1, a 13.6% rise, with the position valued at about $249.31 million. The filing also notes that institutional investors own 79.09% of Ameren stock.
American Electric Power: Pictet's stake reached 1,688,208 shares after purchasing 513,305 additional shares in Q1, representing about 0.31% of the company and valued at roughly $221.29 million.
Atmos Energy: Pictet lifted its holding to 1,175,415 shares in Atmos Energy, a 10.9% increase, roughly 0.71% of the company and valued at about $217.12 million. The stock opened at $174.68 on Friday.
AstraZeneca: Pictet made a new investment in AstraZeneca by purchasing 3,481,864 shares for about $675.26 million, making AZN roughly 0.7% of Pictet's portfolio and its 24th largest holding; the end-quarter stake in AstraZeneca was about 0.22%.
Pictet Asset Management Holding SA made its biggest move of the first quarter by taking a brand-new $675 million stake in AstraZeneca, purchasing 3,481,864 shares of the drugmaker and making it the 24th largest holding in the Swiss firm's portfolio, according to SEC filings. The Geneva-based manager, which oversees roughly $94.8 billion, also deepened its bet on U.S. utilities, lifting positions in Ameren, American Electric Power, and Atmos Energy.
The moves, revealed in Q1 13F filings due by May 15, paint a clear picture: Pictet is rotating into large, stable companies that sit at the intersection of energy infrastructure and healthcare innovation, according to HedgeFollow.
Pictet's $675 Million Bet on AstraZeneca
Pictet had no position in AstraZeneca at the end of 2024. By March 31, 2026, it owned 3,481,864 shares worth about $675 million, equal to roughly 0.7% of its total portfolio. The entry came just weeks after AstraZeneca shifted from Nasdaq-listed American Depositary Receipts to a direct listing on the NYSE under the ticker "AZN" on February 2 — the largest transfer by market capitalization in the exchange's 234-year history, according to PR Newswire.
AstraZeneca CEO Pascal Soriot described the company as "advancing through a catalyst-rich period," citing positive Phase III readouts across 21 new molecular entities currently under review, according to AstraZeneca's Q1 results. For Pictet, the NYSE move likely made entry cleaner and cheaper by removing the administrative layer of ADRs.
American Electric Power Stake Jumps 43.7% on AI Power Demand
Pictet's most aggressive utility move was in American Electric Power. It added 513,305 shares in Q1, lifting its total to 1,688,208 shares worth about $221 million — a 43.7% jump. AEP now represents roughly 0.31% of the company. The timing lines up with AEP's announcement of a $78 billion five-year capital plan to meet surging electricity demand from AI data centers, according to MarketBeat.
AEP expects to add 63 gigawatts of new load by 2030, most of it from large-scale data center clusters, according to TIKR. Some analysts see Pictet's move not as a defensive trade but as a direct bet on AI infrastructure. As Trefis put it, buying AEP is buying the "picks and shovels" of the AI revolution — electricity itself.
Ameren and Atmos Energy Round Out the Utility Push
Pictet added 270,937 Ameren shares in Q1, bringing its total to 2,268,081 shares valued at about $249 million — a 13.6% increase. Analysts currently rate Ameren a "Moderate Buy" with a price target of $119.42, and Simply Wall St estimates the stock is roughly 1% undervalued following a recent Missouri cost recovery filing. Institutional investors now own 81.31% of Ameren stock, according to Business Quant.
In Atmos Energy, Pictet lifted its holding by 10.9% to 1,175,415 shares worth about $217 million, equal to roughly 0.71% of the company. Atmos shares opened at $174.68 on Friday. Pictet's own "Clean Energy Transition" strategy describes natural gas as a "vital bridge" for the 2030 carbon transition, according to Pictet Asset Management, which helps explain the continued buildup in the Dallas-Fort Worth-focused gas utility.
A Defensive Shield or an Aggressive Growth Play?
Analysts are split on what to make of the moves. MarketBeat points to Ameren's low beta of 0.47 and a 2.65% dividend yield — a $3.00 annualized payout — as signs Pictet is building a recession hedge. Utilities with slow, predictable cash flows are classic "bond proxy" holdings when markets turn nervous.
But Steve Freedman, Head of Research and Sustainability for Thematic Equities at Pictet, has said that "investing in evolving technologies is rewarding but risky," justifying the move into stable "AI-adjacent" sectors, according to Trustnet. That framing suggests this is not a retreat — it is a repositioning. Pictet appears to be buying the power grid that runs the AI economy, while also locking in a large-cap healthcare anchor in AstraZeneca.
Sentiment
Mostly PositivePublishers
18
Articles
31
Reach
49
